Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $293.28 million. The enterprise value is $170.06 million.
| Market Cap | 293.28M |
| Enterprise Value | 170.06M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 30.87 million shares outstanding. The number of shares has increased by 435.63% in one year.
| Shares Outstanding | 30.87M |
| Shares Change (YoY) | +435.63% |
| Shares Change (QoQ) | +1.16% |
| Owned by Insiders (%) | 17.56% |
| Owned by Institutions (%) | 69.79% |
| Float | 8.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.42 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.75, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.75 |
| Quick Ratio | n/a |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.50% and return on invested capital (ROIC) is -53.32%.
| Return on Equity (ROE) | -42.50% |
| Return on Assets (ROA) | -39.00% |
| Return on Capital (ROIC) | -53.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.62% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -21.62% |
| 50-Day Moving Average | 6.39 |
| 200-Day Moving Average | 7.20 |
| Relative Strength Index (RSI) | 59.74 |
| Average Volume (30 Days) | 754,208 |
Short Selling Information
The latest short interest is 532,961, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 532,961 |
| Short Previous Month | 484,038 |
| Short % of Shares Out | 1.73% |
| Short % of Float | 5.95% |
| Short Ratio (days to cover) | 0.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -67.10M |
| Pretax Income | -60.39M |
| Net Income | -60.39M |
| EBITDA | -59.07M |
| EBIT | -60.39M |
| Earnings Per Share (EPS) | -$2.74 |
Balance Sheet
The company has $127.87 million in cash and $4.64 million in debt, giving a net cash position of $123.23 million or $3.99 per share.
| Cash & Cash Equivalents | 127.87M |
| Total Debt | 4.64M |
| Net Cash | 123.23M |
| Net Cash Per Share | $3.99 |
| Equity / Book Value | 121.20M |
| Book Value Per Share | 3.93 |
| Working Capital | 116.39M |
Cash Flow
In the last 12 months, operating cash flow was -$42.64 million and capital expenditures -$1.29 million, giving a free cash flow of -$43.93 million.
| Operating Cash Flow | -42.64M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -43.93M |
| FCF Per Share | -$1.99 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -435.63% |
| Shareholder Yield | -435.63% |
| Earnings Yield | -20.59% |
| FCF Yield | -14.98% |
Analyst Forecast
The average price target for ACRV is $20.14, which is 112.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.14 |
| Price Target Difference | 112.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 2.03% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |